anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a preparation method of Capparis spinosa. L selenium polysaccharides. The purpose of the invention is to solve the problem of low antitumor activity of present Capparis spinosa. L polysaccharides. The method comprises the following steps: 1, extracting Capparis spinosa. L polysaccharides; 2, preparing crude Capparis spinosa. L polysaccharides; 3, removing proteins from the crude Capparis spinosa. L polysaccharides; 4, removing pigments and micro-molecular substances from the crude Capparis spinosa. L polysaccharides; 5, carrying out alcohol precipitation on the Capparis spinosa. L polysaccharides; 6, finely extracting the Capparis spinosa. L polysaccharides; and 7, selenizing the Capparis spinosa. L polysaccharides. The preparation method has the advantages of simplicity, easiness in operation, and low cost. The obtained Se-CSPS can substantially inhibit growth of tumors, and the inhibition rate reaches up to 61.08%.
MMF was initiated at a dose of 500 mg twice daily (for patients \> 50 Kg and Estimated Glomerular Filtration rate (eGFR) \> 60 ml/min) for 2 weeks, and advanced to 750 mg twice daily in LN patients weighing less than 50 kg or 1,000 mg twice daily in LN patients weighing 50 kg or more. .
Usual CD treatment, including therapy groups and individual counseling sessions, and six 45-min medical education groups. Physician appointments, pharmacotherapy, and SUD medications were be available as needed.
PROBLEM TO BE SOLVED: To obtain a cosmetic exhibiting excellent foamability under weakly acidic conditions, not having a problem on the point of skin irritation and useful as a base agent, a cleansing agent, an emulsifier or a conditioning agent for hair or skin cosmetics by compounding a specific anion surfactant. SOLUTION: This cosmetic contains an anion surfactant of formula I [(n) is 0 or 1; X is COOH or H; Y is CH2 COOH, CH2 CH2 COOH or the like; R is a 8-20C fatty acid residue] preferably in an amount of 1-50 wt.% based on the total amount of the cosmetic. The anionic surfactant is obtained by acylating a raw material of formula II. When the washability of the anion surfactant is targeted, the long chain fatty acid is preferably a 12C fatty acid, a 14C fatty acid or their mixture. The counter ion includes hydrogen ion, monovalent alkali metal ions and divalent alkaline earth metals. Preferably, the anionic surfactant is used as a partially neutralized salt corresponding to the physiological pH of skin. Examples of the cosmetic include skin milks and skin creams.
The invention concerns a human linker-adhesion molecule 12 and polynucleotide encoding it. The invention also concerns the process of producing the polypeptide by recombinant DNA technique. The methods for treating many diseases e.g. malignant tumor, hemopathy, disorder of embryo development, infection of HIV, immunological diseases and a variety of inflammation etc. utilizing the polypeptide are disclosed. The invention discloses the antagonist against the polypeptide and therapeutics thereof. The invention also discloses the uses of the polynucleotide, which encodes a human linker-adhesion molecule 12.
Mother's head-of-bead elevated 45°. Intervention: Head-of-bed elevated 45°during 2 hours after delivery.
INTRODUCTION: Food desert (FD) residence has emerged as a risk factor for poor outcomes in breast, colon and esophageal cancers. The purpose of this retrospective study was to examine FD residence as an associated risk factor in nonsmall cell lung cancer (NSCLC) patients treated with anatomic lung resection (ALR).
METHODS: All consecutive ALRs for stage I-III NSCLC from January 2015 to December 2017 at a single institution were reviewed. The primary exposure of interest was FD residence as defined by the United States Department of Agriculture. The primary outcome was 5-y overall mortality. Secondary outcomes were 30-d complications and 1- and 3-y mortality. Cox proportional hazard analysis was used to model factors associated with each outcome, adjusted for covariates.
RESULTS: A total of 348 ALRs were included, with 101 (29%) patients residing in an FD. In the unadjusted Cox model, those residing in FD had an associated lower 5-year mortality risk compared to those not residing in an FD (hazard ratio = 0.56, 95% confidence interval (0.33-0.97); P = 0.04). That association was not statistically significant once adjusted for covariates (hazard ratio = 0.59, 95% confidence interval (0.34-1.04); P = 0.07).
CONCLUSIONS: In this study, FD residence was not associated with an increase in the risk of 5-y mortality. Selection bias of patients deemed healthy enough to undergo surgery may have mitigated the negative association of FD residence demonstrated in other cancers. Future work will evaluate all NSCLC patients undergoing treatments at our institution to further evaluate FDs as a risk factor for worse outcomes.
Institutional approval and written informed consent from parents or guardians of healthy children, with obstructive sleep apnea (OSA) and/or with increased end-tidal C02 (sleep related hypoventilation, obstructive hypoventilation or sustained alveolar hypoventilation), confirmed with sleep study, scheduled for elective outpatient or inpatient adeno-tonsillectomy at our hospital, will be obtained. The study will be prospective, randomized, double blinded and placebo controlled. A computer generated randomization list will be used, and the study will be registered with clinical.trials.gov. Written child assent will be obtained from children 7 years and older. Copies of a flyer and an explanation of the study will be provided at the office of all the pediatric ENT surgeons who practice at the Memorial Hermann Hospital OR. The investigators will communicate with the nurses at the surgeons' office and ask them to give the flyer with an explanation of the study to the parents and children on the day they schedule the surgery. The flyer with an explanation of study will be sent to IRB for review and approval. A research assistant will invite parents or guardians in the DSU unit, anesthesia clinic or on the floor to allow their children to be part of the study. Children with OSA and/or increased end tidal C02 (sleep related hypoventilation, obstructive hypoventilation or sustained alveolar hypoventilation), 2-12 years of age, and both genders will be eligible to be part of the study. OSA and its severity will be diagnosed by a preoperative polysomnography. Children with compromised cardiovascular, pulmonary or renal function, those with congenital syndromes, sickle cell disease, history of seizures and those receiving theophylline will be excluded.
Your Magnetic Resonance Image (MRI) results and rTMS calibration information (motor threshold) will be used to create a brain model and identify the targeted location, iTBS coil position and intensity for your iTBS rTMS treatment. You will undergo iTBS rTMS treatment in this study for 6 weeks. There will be 5 iTBS treatment sessions per week, lasting approximately 3 minutes each, once daily for 5 days in a row (always Monday to Friday). Each day after treatment, you will also complete a brief set of questionnaires to track your symptoms, which will take 15 minutes. After every 5 treatments, you will complete an extra interview that will take an additional 30 minutes. There will also be two follow-up visits at 1 and 4 weeks after the end of treatment, each lasting approximately 1 hour. During these follow-up visits, you will be asked to complete a brief set of questionnaires and interviews to monitor your symptoms.
Coronary Computed Tomography Angiography (cCTA) is a non-invasive imaging modality that provides high-resolution images of coronary lesions. cCTA shows good diagnostic performance in detecting or excluding coronary artery stenoses, but the severity of the lesions is often overestimated. With invasive coronary angiography (ICA) the hemodynamic consequences of obstructive lesions can be estimated using Fractional Flow Reserve measurement (FFR). There is a good correlation between FFR and non-invasive ischemia tests such as stress echocardiography, exercise tolerance test or Single Photon Emission Computed Tomography (SPECT). Measurement of FFR during ICA represents the "gold standard" for assessment of the hemodynamic significance of coronary artery lesions. The major disadvantage of FFR is that it is an invasive measurement, and consequently there is a risk of complications. Recently a non-invasive method to determine FFR has been developed (FFRct). FFRct is performed using standard cCTA images, and is based on computational fluid dynamics. The hemodynamic consequence of stenotic lesions is determined at rest and under simulated condition of hyperemia.

Acute myocardial infarction (MI) is divided into STEMI and NSTEMI on the basis of ECG changes. In Denmark patients with STEMI are treated with primary percutaneous intervention (PPCI) of the culprit lesion. Any non-culprit lesions are typically assessed with FFR after 3-4 weeks.

Even though the rate of complications during ICA with FFR is low, these complications can be severe. Also the procedure is quite resource demanding. Thus it would be desirable if it in these patients could be non-invasively evaluated whether further revascularisation is indicated.
INTRODUCTION: Bladder cancer (BCa) with variant histology (VH) is notably aggressive and not as well studied as pure urothelial carcinoma (UC). The characteristics of variant BCa in the setting of metastatic disease may contribute to treatment response/resistance and subsequent disease progression. In this study, we sought to assess VH's impact on metastasis sites at presentation in metastatic BCa.
METHODS: The National Cancer Database was queried from 2004 to 2019 to analyze cT1-4 cN0-3 cM1 patients with UC and VH BCa. The primary endpoint was the presence of metastasis to different organs. Binomial multivariable logistic regression was performed to determine the impact of VH on metastatic sites while controlling for multiple variables.
RESULTS: Total 6005 eligible patients diagnosed with either UC or VH were included. Patients with small cell histology, the second most common VH, were more likely to have liver metastasis (OR: 4.335) while less likely to have lung metastases (OR: 0.521). Squamous cell carcinoma decreased the odds of bone metastasis (OR: 0.449). Adenocarcinoma increased the odds of lung metastases (OR: 1.690). Micropapillary VH is less likely to metastasize to the lungs (OR: 0.182) but more likely to spread to nonregional lymph nodes (OR: 2.623). Sarcomatoid subtype did not exhibit a statistically significant variation in the odds ratio for any of the metastatic sites.
CONCLUSION: This study comprehensively analyzes the limited research regarding metastatic BCa and VH. Our analysis underscores each subtype exhibiting heterogeneous metastatic tropism. Importantly, these findings illustrate the role of routine somatic gene expression profiling to guide adequate staging and treatment intensification and to offer a foundation for future studies of VH BCa care.
There are disclosed formulations, medicated skin treatments, methods of treating acne, pressure-sensitive patches with acne formulations, and skin treatments. In an embodiment, there is provided a formulation of a skin treatment effective in removal of sebum-formed oils from skin of a human body. The formulation includes glycerin, polyvinylpyrrolidone, salicylic acid, and two or more lipophilic vitamin anti-oxidants, and the polyvinylpyrrolidone in a crosslinked configuration by at least one of a chemical process or a radiation process. In an embodiment, there is provided pressure-sensitive adhesive patch configured for application over acne breakouts. The patch includes a fabric material or flexible plastic backing material. The patch includes a formulation carried by the fabric material or the flexible plastic backing material. The formulation is configured to provide a skin treatment effective in removal of sebum-formed oils from the skin of a human body. Other embodiments are also disclosed.
PURPOSE:To obtain a parenteral injection of a benzimidazole-based compound or its salt, capable of being readily formulated into a pharmaceutical preparation, reduced in side effects such as hemolysis with hardly any local irritancy. CONSTITUTION:The objective parenteral injection at pH 9.5-11.5 is composed of a 2-[(2-pyridyl)methylsulfinyl]benzimidazole-based compound having antiulcer action (e.g. omeprazole) or its salt and an aqueous solvent without containing a nonaqueous solvent. This parental injection is prepared by dissolving the benzimidazole-based compound, preferably its salt, together with a strong alkaline substance, in water, etc., for the parenteral injection, regulating the pH to 10.5-12.5, preferably 11-12, preparing an alkaline aqueous solution, then filling the prepared aqueous solution in a vial, suitably replacing the atmosphere in the vial with nitrogen gas, subsequently freeze-drying the aqueous solution according to a well-known method and dissolving the freeze-dried substance in an aqueous solvent (e.g. a physiological saline solution of distilled water for the parenteral injection) without containing a nonaqueous solvent in use. The need for addition of the nonaqueous solvent for enhancing the solubility of the compound which is the active ingredient is eliminated to cancel side effects of the nonaqueous solvent.
BACKGROUND: Postoperative delirium (POD) is a severe perioperative complication that may increase mortality and length-of-stay in older patients. Moreover, POD is a major economic burden to any healthcare system. An altered expression of Acetylcholine- and Butyrylcholinesterases (AChE, BuChE) due to an unbalanced neuroinflammatory response to trauma or an operative stimulus has been reported to play an essential role in the development of POD. We investigated if perioperative measurement of cholinesterases (ChEs) can help identifying patients at risk for the occurrence of POD in both, scheduled and emergency surgery patients.
METHODS: This monocentric prospective observational cohort study was performed in a tertiary hospital (departments of orthopaedic surgery and traumatology). One hundred and fifty-one patients aged above 75 years were enrolled for scheduled (n = 76) or trauma-related surgery (n = 75). Exclusion criteria were diagnosed dementia and anticholinergic medication. Plasma samples taken pre- and postoperatively were analysed regarding AChE and BuChE activity. Furthermore, perioperative assessment using different cognitive tests was performed. The type of anaesthesia (general vs. spinal anaesthesia) was analysed. Primary outcome was the incidence of POD assessed by the approved Confusion Assessment Method (CAM) in combination with the expression of AChE and BuChE.
RESULTS: Of 151 patients included, 38 (25.2%) suffered from POD; 11 (14%) in scheduled and 27 (36%) in emergency patients. AChE levels showed no difference throughout groups or time course. Trauma patients had lower BuChE levels prior to surgery than scheduled patients (p < 0.001). Decline in BuChE levels correlated positively with the incidence of POD (1669 vs. 1175 U/l; p < 0.001). Emergency patients with BuChE levels below 1556 U/L were at highest risk for POD. There were no differences regarding length of stay between groups or incidence of POD. The type of anaesthesia had no influence regarding the incidence of POD. Only Charlson Comorbidity Index and Mini Nutrition Assessment demonstrated reliable strength in respect of POD.
CONCLUSIONS: Perioperative measurement of BuChE activity can be used as a tool to identify patients at risk of POD. As a point-of-care test, quick results may alter the patients' course prior to the development of POD.
TRIAL REGISTRATION: https://drks.de/search/de/trial/DRKS00017178 .
PURPOSE OF REVIEW: The goal of this paper is to aggregate information on monogenic contributions to obesity in the past five years and to provide guidance for genetic testing in clinical care.
RECENT FINDINGS: Advances in sequencing technologies, increasing awareness, access to testing, and new treatments have increased the utilization of genetics in clinical care. There is increasing recognition of the prevalence of rare genetic obesity from variants with mean allele frequency < 5% -new variants in known genes as well as identification of novel genes- causing monogenic obesity. While most of these genes are in the leptin melanocortin pathway, those in adipocytes may also contribute. Common variants may contribute either to higher lifetime tendency for weight gain or provide protection from monogenic obesity. While specific genetic mutations are rare, these segregate in individuals with early-onset severe obesity; thus, collectively genetic etiologies are not as rare. Some genetic conditions are amenable to targeted treatment. Research into the discovery of novel genetic causes as well as targeted treatment is growing over time. The utility of therapeutic strategies based on the genetic risk of obesity is an advancing frontier.
The invention discloses an anti-cancer drug sustained-release preparation of organic-inorganic complex liposome and a preparation method thereof, relating to a sustained-release preparation and preparation method thereof. The invention solves the problems that the existing liposome is not stable, and causes gathering and oxidation phenomena, and drug wrapped by the liposome leaks. The anti-cancer drug sustained-release preparation of organic-inorganic complex liposome is prepared from organic-inorganic complex liposome, phospholipids substance, cholesterol, anti-cancer drug and additive. The first preparation method of the invention is that: 1. preparing mixed solution A; 2. preparing complex liposome film; 3. preparing mixed solution B; and 4. treating the mixed solution B with ultrasonic wave and filtering so as to obtain the anti-cancer drug sustained-release preparation. The second method of the invention is that: 1. preparing mixed solution C; and 2. adding mixed solution C into buffer solution to be stirred until solvent is totally removed, and then obtaining the anti-cancer drug sustained-release preparation. The anti-cancer drug sustained-release preparation of the invention has favorable and stable chemical activity as well as favorable biocompatibility, and produces no gathering and oxidation phenomena. The anti-cancer drug sustained-release preparation of the invention has high envelop rate and drug carrying rate for cancer drugs, and the preparation method of the invention has the advantages of simple technique, moderate reaction condition, good reproduction quality and no pollution.
A composition comprising fat, fibre and, optionally, a stomach antacid is used in the treatment, prevention and/or amelioration of stereotypic behaviours such as crib-biting, stall walking, wind-sucking or wood chewing in animals such as the horse. The preferred sources of fat are highly polyunsaturated vegetable oils such as corn oil, soya oil or processed canola oil, or more saturated fats such as coconut oil, palm oil, or sunflower oil. The preferred source of fibre is any carbohydrate which is not digestible by mammalian enzymes, for example, alfalfa hay, which also contains a high protein content. At least some of the fibre should be in chopped form in the range 1-7 cm in length. Suitable stomach antacids include (a) alkaline salt compounds which can neutralise stomach acid such as aluminum phosphate and dihydro-aluminum sodium carbonate, (b) proton pump inhibitors such as the substituted benzimidazole compound, omeprazole, or (c) histamine type-2 antagonists such as ranitidine or cimetidine. Animal stereotypy may also be treated by controlling the pH of the animal's stomach using a proton pump inhibitor, such as, omeprazole, or a histamine type-2 antagonists.
Tofogliflozin administered once daily for 52 weeks. Insulin administered as base treatment.
The substd. imidazole of the formula (I) is new. (I) is prepd. by reacting the parent ol with an alkyl or phenyl chlorocarbonate and then reacting the product with lysine hydrochloride. The first step is effected at 5-50 deg.C in the presence of an organic base, and the second in an aq. alcohol medium in the presence of an organic amine.
This study will last approximately 6 months. Participants will attend one 1-hour orientation meeting at the beginning of the study and a 2-hour baseline assessment and training meeting. Additional assessments will be conducted at 3 months and 6 months. Weekly questionnaires will be administered. Everyone in the study will be asked to listen to 2 podcasts per week. Each of the podcasts will take about 15 - 20 minutes to listen to and so participants should expect to spend 30 - 40 minutes each week listening to podcasts. Participants will also be randomized to either track diet with an app on their smartphone or using a device they wear on their wrist. Each week, participants will be sent an email as a reminder on how to use their diet tracking device. They will also be encouraged to monitor their exercise and body weight.
Disclosed is a method, comprising operating an end user computer device, performing a storing step (SS). The storing step comprises storing user input data, at least one of a user location set and a third party set, analysis model data, and display data on a data storage component of the end user computer device. The method further comprises performing an analysis step (AS), wherein the analysis step comprises a generation of an estimation of a probability of a medical condition of the user, wherein the generation of the estimation is performed based on the analysis model data, and wherein the generation of the estimation comprises processing the user location set. The method further comprises performing a contact establishment step (CS), which comprises establishing a connection, and wherein the contact establishment step is performed based on the generated estimation. Furthermore, a system comprising an end user computer device is disclosed. The end user computer device is configured for carrying out the disclosed method. The end user computer device furthermore comprises a data storage component, a communication component and an analysis step module, wherein the analysis step module is configured for performing the analysis step.
The development of a potentially life-threatening serotonin syndrome has been reported with MAOIs when used concomitantly with other serotonergic drugs. Such drugs include SSRIs, SNRIs, tricyclic antidepressants, triptans, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John’s wort, S-adenosyl-L-methionine (SAM-e), and other MAOIs used to treat nonpsychiatric disorders (such as linezolid or intravenous methylene blue).

Manifestations of the serotonin syndrome may include mental status changes (e.g., agitation, hallucinations, delirium, coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia; with possible rapid fluctuations of vital signs), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyper-reflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Fatal outcome of serotonin syndrome has been reported, including in patients who had been treated with tranylcypromine sulfate. In some cases of an interaction between tranylcypromine sulfate and SSRIs or SNRIs, the features of the syndrome resembled neuroleptic malignant syndrome.

The concomitant use, or use in rapid succession, of tranylcypromine sulfate with other serotonergic drugs is contraindicated. However, there may be circumstances when treatment with other serotonergic substances (such as linezolid or intravenous methylene blue) is necessary and cannot be delayed. In such cases, tranylcypromine sulfate must be discontinued as soon as possible before initiating treatment with the other agent.

Treatment with tranylcypromine sulfate and any concomitant serotonergic agents should be discontinued immediately if the above events occur, and supportive symptomatic treatment should be initiated.